N/A N=16 Community Central Line Infection Prevention Trial
Infection
Primary: Total Number of Central Line Associated Blood Stream Infections (CLABSI) — 113; 84; 123; 109 infections
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=150 Tranexamic Acid in Knee Joint Surgery
Osteoarthritis
Primary: Blood Loss — 1090; 716; 746 mls — p=<0.05
Phase 3 N=420 An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -1.27; -0.85 Percentage of HbA1c — p=<0.001
Phase 2 N=34 Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
Dementia With Lewy Bodies · REM Sleep Behavior Disorder · Parkinson's Disease Dementia
Primary: Change in the Frequency of REM Sleep Behavior Disorders (RBD) From Baseline to the End of the Treatment Period (28 Days) Based on a Clinical Evaluator. — -1.47; -0.26…
N/A N=45 Ankle Robot to Reduce Foot Drop in Stroke
Stroke · Foot Drop
Primary: Gait Velocity During Self-selected Overground Walking — 0.48; 0.48; 0.54; 0.56 CM/SEC
N/A N=452 A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)
Cystic Fibrosis
Primary: Sweat Chloride by Cohort (Part A Only) — 22.0; 81.0; 101.4 mmol/L
Phase 2 N=10 A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 7 Participants
N/A N=19 Fat Emulsion in Preventing Hypersensitivity Reactions in Patients With Cancer Receiving Carboplatin or Oxaliplatin
Advanced Malignant Neoplasm
Primary: Time-to-carboplatin or Oxaliplatin Acute Hypersensitivity Reaction — 4.4; NA months — p=0.90
Phase 3 N=64 Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
Precocious Puberty, Central
Primary: Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months. — 54 Participants
Phase 1 N=68 A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Neoplasm Metastasis
Primary: Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants
N/A N=1,232 Acquisition of Breast Mammography Images
Breast Cancer
Primary: Number of Participants for Whom Study Image Data Were Collected — 642; 124; 244 Participants
Phase 2 N=16 Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
Colon Cancer · Rectal Cancer
Primary: Efficacy of Lymphoseek for Detection of Sentinel Nodes — 16 Participants
N/A N=10 Transmitted Light Tissue Thickness Analysis (TiLTT)
Morbid Obesity
Primary: Number of Patients With Transmitted Light Intensity to Gastric Wall Thickness) — 10 Participants
N/A N=17 ArcticLine Feasibility Study
Atrial Fibrillation · Atrial Flutter
Primary: Number of Participants With Primary Safety Events With an Onset Date Within 7 Days Post-procedure. — 0 Participants
Phase 2 N=130 B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial
Heart Failure · Heart Failure Acute · Acute Cardiac Pulmonary Edema
Primary: Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management — 7; 10 Participants